Track PURE Bioscience's long-term debt ($3.7M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
The latest long-term debt for PURE is $3.7M as of April 2026. That compares with $4.9M in the prior-year period — down 23.6% year over year. Investors often review this figure alongside PURE Bioscience's historical trend and sector peers before judging valuation or financial health.
Over the past year, PURE's long-term debt moved from $4.9M to $3.7M — a 23.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in PURE Bioscience's operating scale or balance-sheet position.
A long-term debt figure of $3.7M for PURE is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.
After noting PURE's long-term debt ($3.7M), review year-over-year change from $4.9M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.